Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001144204-19-044929
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-17 17:04:28
Reporting Period:
2019-09-17
Accepted Time:
2019-09-17 17:04:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1692830 Satsuma Pharmaceuticals Inc. STSA () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1315082 Ra Capital Healthcare Fund Lp 200 Berkeley Street, 18Th Floor
Boston MA 02116
No No Yes No
1346824 Ra Capital Management, Llc 200 Berkeley Street, 18Th Floor
Boston MA 02116
Yes No Yes No
1384859 Peter Kolchinsky 200 Berkeley Street, 18Th Floor
Boston MA 02116
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-09-17 2,008,409 $0.00 2,008,409 No 4 C Indirect See footnote
Common Stock Acquisiton 2019-09-17 1,340,116 $0.00 3,348,525 No 4 C Indirect See footnote
Common Stock Acquisiton 2019-09-17 1,333,333 $15.00 4,681,858 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2019-09-17 2,008,409 $0.00 2,008,409 $0.00
Common Stock Series B Preferred Stock Disposition 2019-09-17 1,340,116 $0.00 1,340,116 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the issuer's initial public offering.
  2. Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into a share of the issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of issuer's initial public offering.
  3. RA Capital Management, LLC (the "Adviser") is the general partner of the RA Capital Healthcare Fund, L.P.(the "Fund") and the investment adviser for an account owned by a separately managed account (the "Account"). Peter Kolchinsky is the sole manager of the Adviser. The Adviser and Dr. Kolchinsky may be deemed indirect beneficial owners of the securities and they disclaim beneficial ownership of the reported securities: (A) in reliance on Rule 16a-1(a)(1)(v) and (vii); and (B) held by the Fund, for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
  4. The Adviser and Dr. Kolchinsky have no pecuniary interest in the reported securities held in the Account and disclaim: (A) beneficial ownership thereof for purposes of Rule 16a-1(a)(2); and (B) any obligation to file reports under Section 16 other than as a director by deputization. The filing of this Form 4 shall not be construed as an admission that either the Adviser or Dr. Kolchinsky is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the securities held in the Account.
  5. Includes (a) 1,140,946 shares of Common Stock held by the Fund and (b) 192,387 held in the Account, in each case acquired in the issuer's initial public offering.
  6. These securities include 3,923,460 shares held by the Fund and 758,398 shares held in the Account.
  7. Represents 1,642,879 shares held by the Fund and 365,530 shares held in the Account.
  8. Represents 1,139,635 shares held by the Fund and 200,481 shares held in the Account.